Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 4/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.45 |
| ▸ | LONP1 | P36776 | 2/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.41 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15291137 | 0.89 | PSMB5 (0.48) | CLPPPSMB5LONP1PSMB1PSMB2 | |
| SCHEMBL3162016 | 0.88 | CLPP (0.49) | CLPPPSMB5LONP1PSMB1PSMB2 | |
| SCHEMBL3155056 | 0.88 | CLPP (0.49) | CLPPPSMB5LONP1PSMB1PSMB2 | |
| SCHEMBL12754442 | 0.88 | PSMB5 (0.56) | CLPPPSMB5LONP1PSMB1PSMB2 | |
| SCHEMBL3173476 | 0.88 | CLPP (0.48) | CLPPPSMB5LONP1PSMB1PSMB2 | |
| SCHEMBL3169980 | 0.87 | CLPP (0.46) | CLPPPSMB5LONP1PSMB1PSMB2 | |
| SCHEMBL3169974 | 0.87 | CLPP (0.46) | CLPPPSMB5LONP1TAS1R3TAS1R1 | |
| SCHEMBL608358 | 0.87 | CTSS (0.41) | TAS1R3TAS1R1CTSS | |
| SCHEMBL3161989 | 0.85 | CLPP (0.46) | CLPPPSMB5LONP1PSMB1PSMB2 | |
| SCHEMBL3170540 | 0.85 | PSMB5 (0.51) | CLPPPSMB5LONP1PSMB1PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | CLPP 180/4885PSMB5 2/4885LONP1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.